PegBio Co., Ltd. (HKG:2565)

Market Cap	3.45B
Revenue (ttm)	n/a
Net Income	-231.87M
EPS	-0.61
Shares Out	391.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,430,850
Open	9.96
Previous Close	8.82
Day's Range	8.43 - 10.48
52-Week Range	7.46 - 77.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 58
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2565

Financial Performance

Financial numbers in CNY